AtriCure Announces Leadership Promotions

  AtriCure Announces Leadership Promotions

      Focus is on Driving Commercial and Market Development Initiatives

Business Wire

WEST CHESTER, Ohio -- January 14, 2013

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems for the treatment of atrial fibrillation, or
AF, and systems for the exclusion of the left atrial appendage, today
announced three promotions of personnel into key leadership positions.

  *Douglas J. Seith has been promoted to Senior Vice President of Sales and
    Marketing and will be responsible for strengthening commercial execution
    and market development in conjunction with expanding sales. Doug has spent
    nine years at AtriCure and has over 25 years of cardiac surgery,
    cardiology and general surgery sales and sales leadership experience.
    Prior to joining AtriCure, Doug held leadership and/or sales positions
    with A-Med/EmoblX, Inc., Heartport, Inc., Scimed Life Systems, a division
    of Boston Scientific, Inc. and Automated Instruments (a division of United
    States Surgical Corporation).
  *Michael Rogge has been promoted to Vice President of Marketing, and under
    his expanded responsibility, will be focused on market development
    activities and physician education programs that reach newly redefined
    target markets. Mike has over 22 years of medical device experience, the
    past seven with AtriCure building partnerships with Key Opinion Leaders
    (KOLs) and leading customer-driven product development initiatives to
    drive revenue growth. Prior to joining AtriCure, Mr. Rogge held positions
    at Ethicon Endo-Surgery, a Johnson & Johnson Company, Hill-Rom, and Baxter
  *M. Andrew Wade, CPA has been promoted to Vice President and Chief
    Financial Officer. Andy has over 15 years of financial experience, the
    past five with AtriCure building the finance and accounting team. Prior to
    joining AtriCure, Andy held various financial positions with Macy’s Inc.,
    Saks Inc., and Arthur Andersen.

“I am looking forward to the continued contributions from Doug, Mike and Andy
in their new roles, each of whom has been instrumental to AtriCure’s success
to date. These promotions, combined with our focus in building out our
marketing and education initiatives along with our continued international
expansion under Pat Kennedy’s leadership, will help us accelerate growth in
the coming years,” said Mike Carrel, President and Chief Executive Officer of
AtriCure. “Additionally, Andy provides great financial and operational
discipline for AtriCure and we anticipate a seamless transition into his
expanded role as Chief Financial Officer.”

Mr. Carrel continued, “I am pleased with our growth in 2012 which was driven
by the strengths of our technology, product platforms and customer
relationships. As we enter 2013, I am confident in our ability to further
develop and expand our training and education program, and position AtriCure
to achieve its full potential, creating value for customers and shareholders.
I look forward to continuing to build our team of talented and committed
employees at AtriCure."

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing,
manufacturing and selling innovative cardiac surgical ablation systems
designed to create precise lesions, or scars, in cardiac, or heart, tissue for
the treatment of atrial fibrillation, or AF, and systems for the exclusion of
the left atrial appendage. The Company believes cardiothoracic surgeons are
adopting its ablation products for the treatment of AF during concomitant
open-heart surgical procedures and sole-therapy minimally invasive procedures.
AF affects more than 5.5 million people worldwide and predisposes them to a
five-fold increased risk of stroke. The FDA has not cleared or approved
certain AtriCure products for the treatment of AF or a reduction in the risk
of stroke.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments
that AtriCure expects, believes or anticipates will or may occur in the
future, such as earnings estimates, other predictions of financial
performance, launches by AtriCure of new products and market acceptance of
AtriCure’s products. Forward-looking statements are based on AtriCure’s
experience and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many of
which are beyond AtriCure’s control. These risks and uncertainties include the
rate and degree of market acceptance of AtriCure’s products, AtriCure’s
ability to develop and market new and enhanced products, the timing of and
ability to obtain and maintain regulatory clearances and approvals for its
products, the timing of and ability to obtain reimbursement of procedures
utilizing AtriCure’s products, competition from existing and new products and
procedures or AtriCure’s ability to effectively react to other risks and
uncertainties described from time to time in AtriCure’s SEC filings, such as
fluctuation of quarterly financial results, reliance on third party
manufacturers and suppliers, litigation or other proceedings, government
regulation and stock price volatility. AtriCure does not guarantee any
forward-looking statement, and actual results may differ materially from those
projected. AtriCure undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.


AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
Investor Relations Contact:
Westwicke Partners
Lynn Pieper, 415-202-5678
Press spacebar to pause and continue. Press esc to stop.